The program has been enormously successful. According to the nursing staff, parents note that they like the point-of-care test because it is more convenient, and the fingerstick is less scary, invasive, and painful for children than drawing blood from a vein. Since January 2010, Whitney Young has identified 25 children with blood-lead levels of eight micrograms per deciliter or higher (the action level for follow-up in New York state). Screening rates of one- and two-year olds have increased to 83 percent in 2010, versus 73 percent in 2008, before LeadCare II testing began. When high lead levels were found in a local elementary school, the health center organized a rapid response. The staff held two free testing days at the school, using Magellan-loaned LeadCare II analyzers and donated test kits, so they were able to screen about 120 children for lead poisoning. Fortunately, none tested high. However, the immediate results were critical in easing the fears of concerned parents -- and an entire community. Pleased with the improved care for their members, CDPHP has expanded the LeadCare II placement program to three additional Albany-area health centers.
About Magellan (www.magellanbio.com)
Founded in 2004, Magellan's innovative technologies make diagnostic testing easier, more cost-effective, and less labor intensive. The company's products deliver the timely information that clinicians need to make appropriate treatment decisions and improve outcomes for patients. They include LeadCare®-brand rapid point-of-care systems to screen children and adults for lead poisoning; TREK-brand microbiology products for blood culture and susceptibility testing that help in the global effort to pre
|SOURCE Magellan Biosciences|
Copyright©2010 PR Newswire.
All rights reserved